Table 4 Hazard ratio of adverse events among patients treated with triweekly XELOX versus capecitabine
Toxicity | Unadjusted HR for toxicity with triweekly XELOX (95%CI) | P value | PS-adjusted HR for toxicity with triweekly XELOX (95%CI) | P value |
|---|---|---|---|---|
Grade 3–4 toxicities during CRT | ||||
 Any toxicity | 1.447 (0.907–2.309) | 0.121 | 1.392 (0.760–2.550) | 0.284 |
 Leukopenia | 1.880 (0.970–3.644) | 0.061 | 1.857 (0.876–3.937) | 0.107 |
 Neutropenia | 0.961 (0.383–2.410) | 0.933 | 1.117 (0.391–3.189) | 0.836 |
 Anemia | 1.928 (0.120–30.934) | 0.643 | 1.121 (0.257–20.132) | 0.996 |
 Diarrhea | 0.733 (0.370–1.451) | 0.733 | 0.633 (0.222–1.803) | 0.392 |
Postoperative complications | ||||
 Any complication | 1.574 (1.034–2.316) | 0.034* | 1.477 (0.882–2.472) | 0.138 |
 Anastomotic leakage | 1.072 (0.488–2.354) | 0.863 | 0.830 (0.306–2.248) | 0.714 |
 Incision infection | 1.533 (0.686–3.423) | 0.297 | 2.745 (0.885–8.517) | 0.080 |
 Urinary tract infection | 1.101 (0.320–3.794) | 0.879 | 0.832 (2.06–3.368) | 0.797 |
 Pulmonary infection | 1.850 (0.901–3.800) | 0.094 | 1.563 (0.676–3.616) | 0.296 |
 Bowel obstruction | 3.403 (1.324–8.744) | 0.011* | 2.554 (0.711–9.169) | 0.150 |
 Abdominal or pelvic infection | 0.725 (0.317–1.659%) | 0.446 | 0.661 (0.204–2.137) | 0.489 |